Odonate Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 30.650 million compared to USD 27.763 million a year ago. Net loss was USD 30.477 million compared to USD 26.627 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.88 a year ago. For the nine months, operating loss was USD 94.999 million compared to USD 86.221 million a year ago. Net loss was USD 94.064 million compared to USD 83.974 million a year ago. Basic loss per share from continuing operations was USD 3 compared to USD 3.15 a year ago.